Update in mortality in GH-treated patients

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 11, 2013, Pages 4219-4226

  Erfurth, Eva Marie ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ACCIDENT; APLASIA; ARTICLE; BONE CANCER; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CRANIOPHARYNGIOMA; DRUG EFFICACY; GESTATIONAL AGE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPLASIA; INJURY; ISCHEMIA; MORTALITY; NEUROSECRETION; ONSET AGE; OUTCOMES RESEARCH; PRIORITY JOURNAL; SEX RATIO; SHORT STATURE; SUICIDE; TURNER SYNDROME;

CARDIOVASCULAR DISEASES; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; MALE; RISK FACTORS; SEX CHARACTERISTICS;

EID: 84887438134     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2415     Document Type: Article

References (23)

1. Rosén T, Bengtsson BÅ. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336: 285-288.
2. Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf). 1997;46: 75-81.
3. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357: 425-431.
4. Hartman ML, Xu R, Crowe BJ, et al; International HypoCCS Advisory Board. Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab. 2013;98(3): 980-988.
5. Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97(2): 416-425.
6. Sävendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012;97(2):E213-E217.
7. van BunderenCC,van Nieuwpoort IC, Arwert LI, et al. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab. 2011;96(10): 3151-3159.
8. Gaillard RC, Mattsson AF, Akerblad AC, et al. Overall and causespecific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol. 2012;166(6): 1069-1077.
9. Burman P, Mattsson AF, Johannsson G, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab. 2013;98(4): 1466-1475.
10. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95(1): 167-177.
11. Stochholm K, Juul S, Christiansen JS, Gravholt CH. Mortality and socioeconomic status in adults with childhood onset GH deficiency (GHD) is highly dependent on the primary cause of GHD. Eur J Endocrinol. 2012;167(5): 663-670.
12. World Health Organization. The Global Burden of Disease - 2004 Update. Geneva, Switzerland: World Health Organization; 2008.
13. Holmer H, Svensson J, Rylander L, et al. Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone. J Clin Endocrinol Metab. 2007;92(9): 3560-3567.
14. Erfurth EM, Bülow B, Svahn-Tapper G, et al. Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab. 2002;87: 4892-4899.
15. Nielsen EH, Lindholm J, Laurberg P. Excess mortality in women with pituitary disease: a meta-analysis. Clin Endocrinol (Oxf). 2007;67(5): 693-697.
16. LaCroix AZ, Chlebowski RT, Manson JE, et al WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13): 1305-1314.
17. Erfurth EM, Hagmar L. Cerebrovascular disease in patients with pituitary tumors. Trends Endocrinol Metab. 2005;16(7): 334-342.
18. Sherlock M, Reulen RC, Alonso AA, et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab. 2009;94(11): 4216-4223.
19. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002;87:3136-3141
20. Agha A, Monson JP. Modulation of glucocorticoid metabolism by the growth hormone-IGF-1 axis. Clin Endocrinol (Oxf). 2007; 66(4): 459-465.
21. Erfurth EM, Holmer H, Fjalldal SB. Mortality and morbidity in adult craniopharyngioma. Pituitary. 2013;16(1): 46-55.
22. Rosenfeld RG, Cohen P, Robison LL, et al. Long-term surveillance of growth hormone therapy. J Clin Endocrinol Metab. 2012;97(1): 68-72.
23. Malozowski S. Reports of increased mortality and GH: will this affect current clinical practice? J Clin Endocrinol Metab. 2012; 97(2): 380-383.